Adma Biologics (ADMA) Other Accumulated Expenses (2016 - 2026)

Adma Biologics (ADMA) has 8 years of Other Accumulated Expenses data on file, last reported at $4.2 million in Q4 2025.

• Quarterly Other Accumulated Expenses rose 108.82% year-over-year to $4.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.2 million (up 108.82% YoY) and the FY2025 annual result came in at $4.2 million, up 108.82% from the prior year.
• Other Accumulated Expenses climbed to $4.2 million in Q4 2025, from $2.6 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $17.5 million in Q2 2025 to a low of $981721.0 in Q4 2021.
• A 5-year average of $3.1 million and a median of $2.3 million in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses plunged 33.89% — and 2025, when it jumped 663.13%.
• Tracing ADMA's Other Accumulated Expenses over 5 years: stood at $981721.0 in 2021, then soared by 82.94% to $1.8 million in 2022, then jumped by 31.68% to $2.4 million in 2023, then retreated by 15.6% to $2.0 million in 2024, then surged by 108.82% to $4.2 million in 2025.
• The last three Other Accumulated Expenses figures came in at $4.2 million (Q4 2025), $2.6 million (Q3 2025), and $17.5 million (Q2 2025), per Business Quant data.